Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (800)	5/3/2001 4:23:32 PM
From: keokalani'nui	Read Replies (1) of 834

From 1Q01 CC: Company believes its ETi's are the most potent and selective of all in class; that the selective ET-As will be most therapeutic; and that leaving ET-B alone is beneficial by allowing more vasodilation. As opposed to Actelion (class 3,4), txb's ETi's are being given to class 2, 3 and 4 pts. Once-a-day dosing. 2nd gen is much more selective for ET-A and more potent, (possibly longer-acting?). Sitaxsentan (1st gen) is once-a-day. Both are into the clinic in the ICOS-TXB JV, in PHT first (2nd gen will either be tested in follow on PI with serial doing, and then in CHF or PHT in a P2 maybe beginning 1Q02). Not letting up on 1st gen, clearly going to take it as far as it can go. Have been encouraged by the Actelion results (hemodynamics), and weren't surprised by the lack of clinical benefits given the acute setting and admin on top of nitro and other agents. Estimate of Argatroban sales in '01 are $16m - $20m. Expecting much more as time goes by and GSK ploughs the field. Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next